Earnings Preview: GlaxoSmithKline, Barclays, Enersis, Praxair

Earnings Preview: GlaxoSmithKline, Barclays, Enersis, Praxair
geralt / Pixabay

A number of corporations in different industries will report its financial performance for the first quarter of the current fiscal year on Wednesday, April 24 including GlaxoSmithKline plc (NYSE:GSK) (LON:GSK), Enersis S.A. (NYSE:ENI), Owens Corning (NYSE:OC), and Praxair, Inc. (NYSE:PX).

Earnings Preview: GlaxoSmithKline, Barclays, Enersis, Praxair

Over the past three months, analysts covering GlaxoSmithKline plc (NYSE:GSK) (LON:GSK) became increasingly concerned regarding the profitability of the company. Seven out of 10 analysts recommended a hold rating for the stock.

Gates Capital Management Reduces Risk After Rare Down Year [Exclusive]

Gates Capital Management's ECF Value Funds have a fantastic track record. The funds (full-name Excess Cash Flow Value Funds), which invest in an event-driven equity and credit strategy, have produced a 12.6% annualised return over the past 26 years. The funds added 7.7% overall in the second half of 2022, outperforming the 3.4% return for Read More

Based on data from Bloomberg, the consensus first quarter earnings estimate for the company is £0.26 per share and its revenue will be around £6.4 billion. For fiscal 2013, analysts projected that GlaxoSmithKline will achieve £1.15 per share and £26.9 billion revenue.

During the previous fourth quarter of 2012, the company recorded £6.8 billion revenue and £0.31 earnings per share. Its full year revenue was £26.4 billion and £1.11 earnings per share.

GlaxoSmithKline plc (NYSE:GSK) (LON:GSK) expect to achieve a core EPS growth of 3 percent to 4 percent CER this year and about 1 percent CER sales growth. For the first quarter, the company expected a sales decline due to year-on-year comparative factors.

Most recently, the company together with Theravance Inc (NASDAQ:THRX), submitted its regulatory application for ANORO ELLIPTA, the investigational once-daily LAMA/LABA combination medicine for patients with chronic obstructive pulmonary disease (COPD) to the Japanese Ministry of Health Labor and Welfare.

The FDA Advisory Committee recently recommended the approval of BREO ELLIPTA, a once-daily inhaled treatment for the long-term maintenance treatment of airflow obstruction in patients with COPD.

Since July 2012, the stock price of European banks such as Barclays PLC (NYSE:BCS) (LON:BARC), demonstrated an outstanding performance. Over the past 52-week range, the stock price of the bank climbed from the lowest level at $9.23 per share to its highest level at $20.60 per share. The shares of Barclays are trading around $17.93 per share after trading hours on Monday.

For the first quarter of 2013, the consensus estimate for Barclays PLC (NYSE:BCS) (LON:BARC)’s total income net of insurance claims is approximately £7.8 billion, net operating income of around £6.9 billion, and its profit before tax at about  £1.85 billion.

For its Investment Bank, the consensus estimate for its total income is approximately £3.3 billion, net operating income of around £3.2 billion, and profit before tax is around £1.9 billion.

For the full year 2013, Barclays PLC (NYSE:BCS) (LON:BARC) is expected to achieve £29.24 billion total income net of insurance claims, £25.79 billion net operating income, £6.6 billion profit before tax, £35.80 earnings per share, and a dividend of £7.30 per share.

Analysts covering Barclays stock recommended a strong buy rating and the consensus 12-month price target is $20.24 per share while the highest price target is $26.66 per share.

On the other hand, Enersis S.A. (NYSE:ENI), one of the largest electricity companies in South America has more than 14 million clients. In 2012, the company increased its distribution by 3,552 GWh and added 360,000 new customers. Despite an increased demand for electricity in the areas of its operation, unfavorable hydrological conditions affected its financial performance. Its EBITDA decreased by 6.8 percent to $4.07 million, $13.5 million revenue and $1.8 million net income.

For 2013, the management of the company expected that the demand for electricity in the five countries of its business operation will grow by 5 percent. However, the company expects challenges such as tariff reviews for Edelnor, Codensa, and Ampla power plants, and regulatory frameworks in Chile and Argentina.

In March, the company completed its transaction to consolidate the assets of its parent company in Latin America and sold out all of its 16.44 billion shares. The company said it will use the proceeds of the transaction for its operations in the region.

Meanwhile, Analysts expect Owens Corning (NYSE:OC) to report a solid earnings performance for the first quarter of 2013. The consensus earnings estimate for the company is $0.19 per share, up 52.6 percent. During the same quarter in the previous year, the company posted $0.09 earnings per share. The company is estimated to report $5.52 billion revenue.

Nine analysts recommended a hold rating for the stock and four analysts recommended a strong buy. The consensus price target for the shares of Owens Corning (NYSE:OC) is $45.90 per share.

Majority of analysts are bullish with Praxair, Inc. (NYSE:PX) and they recommend a buy rating for its shares. Over the past 52-week range its stock price increased from $100 per share to its highest level of $116.93 per share. The stock is trading around $110 per share on Tuesday morning.

Analysts expect the company to report $1.36 earnings per share, a 5.4 percent increase from its previous result in the same period last year. Its estimated revenue is around $2.83 billion compared with its $2.7 billion revenue a year ago. For the fiscal 2013, its total revenue is expected to be approximately $11.9 billion.

No posts to display